Traduction de «may be generated » (Néerlandais → Français) :

TERMINOLOGIE

blootstelling aan elektrische stroom van onafhankelijke generator met passage van stroom door weefsel
exposition au courant électrique d'un générateur indépendant, avec passage de courant à travers un tissu

draagbare generator voor diagnostisch röntgensysteem
générateur portatif pour système de radiodiagnostic

mobiele generator voor diagnostisch röntgensysteem
générateur mobile pour système de radiodiagnostic

generator voor systeem voor antimitotische kankerbehandeling met wisselend elektrisch veld
générateur de système de traitement antimitotique du cancer par champ électrique alternatif

generator voor iontoforesesysteem voor geneesmiddelafgifte
générateur de système d’administration de médicament par ionophorèse

generator voor geactiveerde zuurstof
générateur d’oxygène actif

generator voor tandheelkundig ozonsysteem
générateur de système d’ozone dentaire

generator voor luchtwegklaringssysteem op basis van borstkas-oscillatie
générateur pour système de décollement des sécrétions des voies aériennes par oscillations thoraciques

generator voor behandelsysteem voor hemorroïden
générateur pour système de traitement des hémorroïdes

generator voor endodontisch obturatiesysteem
générateur de système d’obturation endodontique

TRADUCTIONS EN CONTEXTE

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.